Sirenia Capital Management LP Reports New 9.9% Stake in Ovid Therapeutics Inc.

Sirenia Capital Management LP, along with Alex Silverstein, filed a Schedule 13G on May 15, 2026, reporting a new 9.9% stake in Ovid Therapeutics Inc. (OVID). The reporting persons beneficially own 18,031,333 shares of common stock, which includes 8,552,333 shares issuable upon the exercise of warrants held by SILV Fund, Ltd., an investment fund managed by Sirenia. The filing notes that the warrants are subject to a 9.99% beneficial ownership blocker, meaning the reporting persons cannot exercise warrants that would result in owning more than 9.99% of the outstanding common stock. The ownership calculation is based on an aggregate of 151,028,955 shares outstanding, factoring in the company's March 2026 private placement. Sirenia acquired these securities in the ordinary course of business, and the filing indicates this is a passive investment without the intent to influence control over the issuer. Alex Silverstein, as the managing member of Sirenia's general partner, shares voting and dispositive power over the reported securities.